{"title":"左旋酒石酸的体内降血糖和降血脂作用","authors":"Ayoub Amssayef, Mohamed Eddouks","doi":"10.2174/1871529X23666221202091848","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>The aim of the study was to investigate the antihyperglycemic effect of L-Tartaric acid.</p><p><strong>Background: </strong>L-Tartaric acid is a natural product with possible beneficial effects on health.</p><p><strong>Objective: </strong>The goal of this work was to evaluate the antihyperglycemic and antidyslipidemic effects of L-Tartaric acid (L-TA) in rats.</p><p><strong>Materials and methods: </strong>In the first model, the effects of L-TA (10 and 40 mg/kg) on diabetes conditions induced by streptozotocin (STZ) in rats were investigated. In the second model, the effects of L-TA (40 and 80 mg/kg) on dyslipidemia induced by tyloxapol (Triton WR-1339) in rats were assessed.</p><p><strong>Results: </strong>L-TA (40 mg/kg) had improved all studied parameters. L-TA at 40 mg/kg was able to significantly reduce glycaemia, improve oral glucose tolerance (OGT), increase glycogen content in liver and extensor digitorum longus (EDL) muscle, and ameliorate the lipidic profile and atherogenic indices in STZ-diabetic rats.</p><p><strong>Conclusion: </strong>L-Tartaric acid was able to exhibit antihyperglycemic and antidyslipidemic effects in STZ-induced diabetic rats. Moreover, the antidyslipidemic effect of L-Tartaric acid was confirmed in tyloxapol-induced hyperlipidemic rats.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":" ","pages":"185-198"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In vivo Antihyperglycemic and Antidyslipidemic Effects of L-Tartaric Acid.\",\"authors\":\"Ayoub Amssayef, Mohamed Eddouks\",\"doi\":\"10.2174/1871529X23666221202091848\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>The aim of the study was to investigate the antihyperglycemic effect of L-Tartaric acid.</p><p><strong>Background: </strong>L-Tartaric acid is a natural product with possible beneficial effects on health.</p><p><strong>Objective: </strong>The goal of this work was to evaluate the antihyperglycemic and antidyslipidemic effects of L-Tartaric acid (L-TA) in rats.</p><p><strong>Materials and methods: </strong>In the first model, the effects of L-TA (10 and 40 mg/kg) on diabetes conditions induced by streptozotocin (STZ) in rats were investigated. In the second model, the effects of L-TA (40 and 80 mg/kg) on dyslipidemia induced by tyloxapol (Triton WR-1339) in rats were assessed.</p><p><strong>Results: </strong>L-TA (40 mg/kg) had improved all studied parameters. L-TA at 40 mg/kg was able to significantly reduce glycaemia, improve oral glucose tolerance (OGT), increase glycogen content in liver and extensor digitorum longus (EDL) muscle, and ameliorate the lipidic profile and atherogenic indices in STZ-diabetic rats.</p><p><strong>Conclusion: </strong>L-Tartaric acid was able to exhibit antihyperglycemic and antidyslipidemic effects in STZ-induced diabetic rats. Moreover, the antidyslipidemic effect of L-Tartaric acid was confirmed in tyloxapol-induced hyperlipidemic rats.</p>\",\"PeriodicalId\":9543,\"journal\":{\"name\":\"Cardiovascular and Hematological Disorders - Drug Targets\",\"volume\":\" \",\"pages\":\"185-198\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular and Hematological Disorders - Drug Targets\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1871529X23666221202091848\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Disorders - Drug Targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X23666221202091848","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
In vivo Antihyperglycemic and Antidyslipidemic Effects of L-Tartaric Acid.
Aims: The aim of the study was to investigate the antihyperglycemic effect of L-Tartaric acid.
Background: L-Tartaric acid is a natural product with possible beneficial effects on health.
Objective: The goal of this work was to evaluate the antihyperglycemic and antidyslipidemic effects of L-Tartaric acid (L-TA) in rats.
Materials and methods: In the first model, the effects of L-TA (10 and 40 mg/kg) on diabetes conditions induced by streptozotocin (STZ) in rats were investigated. In the second model, the effects of L-TA (40 and 80 mg/kg) on dyslipidemia induced by tyloxapol (Triton WR-1339) in rats were assessed.
Results: L-TA (40 mg/kg) had improved all studied parameters. L-TA at 40 mg/kg was able to significantly reduce glycaemia, improve oral glucose tolerance (OGT), increase glycogen content in liver and extensor digitorum longus (EDL) muscle, and ameliorate the lipidic profile and atherogenic indices in STZ-diabetic rats.
Conclusion: L-Tartaric acid was able to exhibit antihyperglycemic and antidyslipidemic effects in STZ-induced diabetic rats. Moreover, the antidyslipidemic effect of L-Tartaric acid was confirmed in tyloxapol-induced hyperlipidemic rats.
期刊介绍：
Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
